Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman

Lexaria Bioscience Corp.

Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.
Christopher receives 200,000 stock options at $3.92, base salary with 5% annual raises in 2025-26, and 50% of salary bonus target.
Outgoing CEO Bunka's letter: $8.5M raised YTD 2024, market cap ~$60M, Phase 1b hypertension study expected H1 2025.
GLP-1 R&D shows positive data; DehydraTECH-CBD outperforms in weight loss and blood sugar control in animal studies.
Bunka remains Chairman and Executive Strategic Advisor; cites need for pharma operational expertise for execution phase.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Christopher

Chief Executive Officer

LEXX · Lexaria Bioscience Corp.

Effective: 2024-08-31
Filed: September 5, 2024, 7:59 PM ET

appointed Richard Christopher, age 54, to the position of Chief Executive Officer

Role change

Christopher Bunka

Chairman of the Board

LEXX · Lexaria Bioscience Corp.

Effective: 2024-08-31
Successor: Richard Christopher
Filed: September 5, 2024, 7:59 PM ET

replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Christopher was appointed as Chief Executive Officer at Lexaria Bioscience Corp..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Richard Christopher, age 54, to the position of Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Bunka changed role as Chairman of the Board at Lexaria Bioscience Corp..

Role: Chairman of the Board

Exact text from the filing

replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor

View on SEC.gov

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-24-001396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.